Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Alnylam Pharmaceuticals, Inc. (ALNY) had Free Cash Flow per Share of $0.35 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.17B |
|
$205.99M |
|
$211.12M |
|
$956.05M |
|
$898.54M |
|
$268.64M |
|
$-46.98M |
|
$221.65M |
|
$221.65M |
|
$205.99M |
|
$205.99M |
|
$205.99M |
|
$205.99M |
|
$268.64M |
|
$282.19M |
|
132.89M |
|
138.23M |
|
$1.55 |
|
$1.51 |
|
| Balance Sheet Financials | |
$4.22B |
|
$518.26M |
|
$910.24M |
|
$5.13B |
|
$1.35B |
|
$1.01B |
|
$2.70B |
|
$4.05B |
|
$1.08B |
|
$1.08B |
|
$1.08B |
|
133.44M |
|
| Cash Flow Statement Financials | |
$70.50M |
|
$-25.54M |
|
$15.71M |
|
$1.66B |
|
$1.71B |
|
$53.61M |
|
$70.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.13 |
|
-- |
|
-- |
|
0.48 |
|
0.94 |
|
81.91% |
|
23.02% |
|
23.02% |
|
-- |
|
18.99% |
|
17.65% |
|
$48.67M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
2.51 |
|
1.32 |
|
68.16 |
|
19.16% |
|
19.16% |
|
4.02% |
|
9.88% |
|
$8.06 |
|
|
Free Cash Flow per Share |
$0.35 |
$0.51 |
|